Hanmi Pharmaceutical said it posted 1.33 trillion won in revenue in 2022, the largest ever in the company’s history, thanks to the sales growth of self-developed drugs including the dyslipidemia combo. 

According to the company’s public filing of the preliminary 2022 earnings on Wednesday, Hanmi’s revenue reached 1.33 trillion won, a 10.7 percent increase from a year earlier. Operating profit rose 25.2 percent on-year to 157 billion won, and net profit, 17.4 percent to 95.7 billion won. 

Hanmi attributed the robust sales growth to its self-developed medicines. In 2022, Hanmi raised 789.1 billion won in outpatient prescription sales. Sales of Rosuzet, a dyslipidemia combination drug mixing ezetimibe and rosuvastatin calcium, reached 140.3 billion won alone. Hypertension drug Amosartan products sold 130.5 billion won, the company said. 

“The latest sales surpassed the 2015 sales of 1.31 trillion won, which had been the largest with the nation’s largest-ever new drug licensing deal,” Hanmi Pharmaceutical said.

Hanmi spent about 177.9 billion won, or 13.4 percent of the revenue, on R&D. 

Beijing Hanmi Pharmaceutical, a Chinese subsidiary of Hanmi, achieved 350.6 billion won in sales, 78 billion won in operating profit, and 71.5 billion won in net profit, in 2022. 

Hanmi Science, the holding company of Hanmi Group, recorded 1.04 trillion won in sales, 65.9 billion won in operating income, and 55.5 billion won in net income, last year.

Hanmi Science merged with its affiliate Hanmi Healthcare in 2022. Subsidiaries of Hanmi Science include Hanmi Pharmaceutical, JVM, a manufacturer of hospital & pharmacy automation systems, and Online Pharm, a drug distributor.